It has been reported that abnormalities of the ubiquitin–proteasome system together with increased expressions of MuRF-1 and MAFbx are associated with muscle atrophy in diseases such as cancer cachexia, sarcopenia of aging, chronic kidney disease, diabetes, and chronic obstructive pulmonary disease [38]. Here, FBXO32 is linked to muscle atrophy.